A different room, a different population
ZUPREME-2 · Completed August 13, 2026 · Sponsor report October 7, 2026
What changes when the participants also have type 2 diabetes?
Subject One tries to carry the previous chart into a room marked TYPE 2 DIABETES. Doctide stops him at the threshold and hands him a different folder. He leaves the first chart where it belongs. This room has its own people, its own comparison, and its own unanswered questions.
What changes here
The diabetes readout is encouraging sponsor-reported evidence, not the full published trial. [1]
Read the study details & dates
Completed phase 2 trial; denominators differ across sources
The registry lists 221 enrolled; the October 7 sponsor release reports 220. The difference is not resolved in the reviewed sources. The randomized, double-blind comparison used three weekly subcutaneous petrelintide arms versus placebo in adults with overweight/obesity and type 2 diabetes, with lifestyle measures and background metformin with or without an SGLT2 inhibitor. [2] [1]
Reported results at 28 weeks
Mean weight reduction was 7.4–9.2% across petrelintide arms versus 2.0% with placebo using the efficacy estimand. Placebo-adjusted HbA1c reductions were 0.61–0.88 percentage points. Gastrointestinal adverse events led to discontinuation in 1.9% versus 1.7%. [1]
What this does not establish
The announcement is not a peer-reviewed full paper. Complete statistical and safety tables remain necessary; do not combine these results with the non-diabetes trial or rank medicines across separate studies.
Original sources
- Zealand Pharma sponsor topline announcement — ZUPREME-2, October 7, 2026 (not a peer-reviewed paper)
- ClinicalTrials.gov — NCT06926842, ZUPREME-2
Reviewed October 20, 2026: Zealand's October 7 sponsor announcement and ClinicalTrials.gov record updated September 9. No results tables were posted in the registry at this check.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story